ALS drug will be pulled from US market after study showed patients didn't benefit

  • 📰 KPRC2
  • ⏱ Reading Time:
  • 32 sec. here
  • 4 min. at publisher
  • 📊 Quality Score:
  • News: 23%
  • Publisher: 68%

Health News

Washington News,Business

The maker of a drug for Lou Gehrig’s disease that recently failed in a study says it will pull the medicine from the U.S. market.

ASK 2: What should you do when a driver comes to an intersection with a flashing yellow left turn arrow?Business

Amylyx Pharmaceuticals announced it will voluntarily halt sales and marketing of the drug in the U.S. and Canada, where new patients will no longer be able to get a prescription.“While this is a difficult moment for the ALS community, we reached this path forward in partnership with the stakeholders who will be impacted and in line with our steadfast commitment to people living with ALS," company executives said in a statement.

Relyvrio is a powder that combines two older drugs: a prescription medication for liver disorders and a dietary supplement associated with traditional Chinese medicine.

We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more:

 /  🏆 80. in US
 

Thank you for your comment. Your comment will be published after being reviewed.
Please try again later.

United States United States Latest News, United States United States Headlines